Cerevel Therapeutics Holdings, Inc.
CERE · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.05 | -0.32 | -0.76 | -0.46 |
| FCF Yield | -5.04% | -6.23% | -4.27% | -6.98% |
| EV / EBITDA | -14.40 | -13.60 | -20.15 | -10.82 |
| Quality | ||||
| ROIC | -38.79% | -38.81% | -33.49% | -35.69% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.79 | 0.83 | 0.79 | 0.77 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -16.48% | -57.18% | -38.30% | -90.33% |
| Safety | ||||
| Net Debt / EBITDA | 1.16 | -0.63 | 0.74 | 2.36 |
| Interest Coverage | -42.33 | -38.24 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | -2.40 | -3.75 | 0.00 |
| Cash Conversion Cycle | -769.50 | -901.30 | -1,607.42 | -4,590.54 |